Human Genome Sciences Inc (HGSI): Today's Featured Drugs Loser
(
) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 1.6%. By the end of trading, Human Genome fell 26 cents (-1.9%) to $13.62 on average volume. Throughout the day, 6.7 million shares of Human Genome exchanged hands as compared to its average daily volume of eight million shares. The stock ranged in price between $13.41-$13.83 after having opened the day at $13.78 as compared to the previous trading day's close of $13.88. Other company's within the Drugs industry that declined today were:
(
), down 42.9%,
Catalyst Pharmaceutical Partners
(
), down 34.5%,
(
), down 9.3%, and
(
), down 5.9%.
Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. Its principal products include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. Human Genome has a market cap of $2.79 billion and is part of the
sector. Shares are up 87.8% year to date as of the close of trading on Wednesday. Currently there are eight analysts that rate Human Genome a buy, no analysts rate it a sell, and 12 rate it a hold.
TheStreet Ratings rates Human Genome as a
. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and generally weak debt management.
- You can view the full Human Genome Ratings Report.
On the positive front,
(
), up 47.9%,
(
), up 44.9%,
(
), up 29.8%, and
(
), up 27%, were all gainers within the drugs industry with
(
) being today's featured drugs industry winner.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null
